Tempus AI (TEM) Faces A Valuation Test As It Expands Into Whole Genome Sequencing

Tempus AI (TEM) just outlined a major push into whole genome sequencing, planning a research platform of 100,000 fully sequenced genomes tied to rich clinical records for AI driven disease analysis.

Tempus AI’s whole genome push lands at a time when momentum in the shares has been building, with a 30 day share price return of 19.66% and a 90 day move of 46.49%, even though the 1 year total shareholder return sits at 6.35%.

Review a curated set of 38 healthcare AI stocks, already filtered for AI and genomics themes, to compare Tempus AI with peers influenced by similar catalysts.

Tempus AI now trades above the average analyst target, after a steep multi month climb. So where does a reasonable fair value range actually land for this kind of growth story?

Most Popular Narrative: 8.7% Overvalued

Tempus AI last closed at $82.24. The most followed narrative on the stock points to a fair value of $75.68, which puts the current quote modestly ahead of that framework and raises questions about how much of the whole genome story is already in the price.

This data moat is what makes the business interesting. Tempus has accumulated tens of millions of de-identified patient records and hundreds of petabytes of clinical and molecular data, assets that would take competitors years and enormous investment to replicate.

See why 27 investors see Tempus AI as 9% overvalued.

Result: Fair Value of $75.68 (OVERVALUED)

Still, the Tempus AI story can break if whole genome adoption is slower than hoped, or if ongoing net losses make investors question the data flywheel thesis.

Find out about the key risks to this Tempus AI narrative.

Next Steps

Mixed feelings about Tempus AI after this move higher and the whole genome push are understandable. Check the underlying data quickly and weigh the 1 key reward and 2 important warning signs.

Looking for more Tempus AI style investment ideas?

If Tempus AI has your attention, do not stop here. Use Simply Wall St's screener to uncover fresh opportunities that fit your own risk and return preferences.

• Target potential mispricings across the market and see which companies screen as attractively valued through the 30 high quality undervalued stocks.
• Prioritise resilience and focus on businesses with stronger balance sheets by scanning the list of solid balance sheet and fundamentals (23 results).
• Hunt for underfollowed opportunities that may not be on many investors' radars yet by reviewing the 16 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com